Allogeneic hemopoietic SCT for patients with primary myelofibrosis: A predictive transplant score based on transfusion requirement, spleen size and donor type

A. Bacigalupo, M. Soraru, A. Dominietto, S. Pozzi, S. Geroldi, M. T. Van Lint, A. Ibatici, A. M. Raiola, F. Frassoni, F. De Stefano, S. Verdiani, L. Casarino, G. Barosi

Research output: Contribution to journalArticlepeer-review

Abstract

A total of 46 patients with primary myelofibrosis (PMF) (median age 51 years), underwent an allogeneic hemopoietic SCT (HSCT) after a thiotepa-based reduced-intensity conditioning regimen. The median follow-up for surviving patients is 3.8 years. In multivariate analysis, independent unfavorable factors for survival were RBC transfusions >20, a spleen size >22cm and an alternative donor24 patients had 0-1 unfavorable predictors (low risk) and 22 patients had 2 or more negative predictors (high risk). The overall actuarial 5-year survival of the 46 patients is 45. The actuarial survival of low-risk and high-risk patients is, respectively, 77 and 8 (P

Original languageEnglish
Pages (from-to)458-463
Number of pages6
JournalBone Marrow Transplantation
Volume45
Issue number3
DOIs
Publication statusPublished - 2010

Keywords

  • Allogeneic transplant
  • Myelofibrosis
  • Reduced intensity regimens

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Allogeneic hemopoietic SCT for patients with primary myelofibrosis: A predictive transplant score based on transfusion requirement, spleen size and donor type'. Together they form a unique fingerprint.

Cite this